Immuno-theraTRACE™ Oncology Screening
Uncover the Immunotherapeutic Potential of Your Compound
As the field of precision medicine advances, the demand for targeted and tumor-specific immune-modulating agents is increasing. Our oncology platform, immuno-theraTRACE™, allows you to screen your immune-modulating agents for their therapeutic potential across a range of tumor types.
When you partner with Melior, you get the data you need to quickly and confidently determine which cancer type to advance your immunotherapy toward.
Harness the Power of the Immune System
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by leveraging T-cell-based antitumor immunity. However, to effectively evaluate an immunotherapeutic agent as an antitumor agent, you need to test it in the context of an intact immune system. By developing a study design incorporating multiple syngeneic mouse models, we can help you determine which tumor type your therapeutic candidate is most effective against.
“Cold tumors,” characterized by the absence of T-cell infiltration, show poor ICI response rates due to multiple mechanisms mediating T-cell exclusion. Several approaches have been shown to improve the efficacy of ICIs by “firing-up” cold tumors and driving T-cell infiltration1.
With Immuno-theraTRACE™, you can screen your immune-modulating agents, including ICIs, across various tumor types that range from hot to cold.
Leverage Custom-fit Study Designs Tailored to Your Objectives
Our agile team uses custom designs, short lead times, and transparency to get the answers you need, when you need them.
Custom study designs
High throughput mode: Simultaneously test multiple compounds in smaller groups of animals. Our studies reveal low standard deviations in tumor sizes, allowing for small group sizes and higher signal-to-noise ratios for accurately detecting therapeutic effects.
Lead candidate mode: Analyze multiple doses of a single compound within larger group sizes for more powerful results.
Short lead times
Get critical data sooner through our team of scientists who deliver results faster than most CROs.
Highly interactive project managers
Stay up-to-date with your study’s process at all times through our passionate, transparent project managers.
Maximize Your Study Findings with Complementary Data Sets
Get the most out of your study by integrating custom services and analyses. We help design your study and suggest additional opportunities for more robust data sets.
Some of our complementary services include:
- Tissue collection for immune cell analysis and profiling
- Whole blood, spleen, and lymph node analysis
- General observations
- Metabolic analyses
- Histology and IHC
- Pain analysis
- IVIS imaging
- PK studies
Looking for something else to complement your data set?
What to Expect When Working with Us
Our process is designed to give you the answers you’re looking for. When you work with us, we take the time to understand your project goals. From there we’ll work together to develop a study that balances your needs, budget, and timeline. Expect open lines of communication throughout the study execution, we avoid surprises and exceed expectations.
Our process
- Discovery: Let’s meet on Zoom to discuss your study request. Our experts will serve as consultants to make sure your research questions are properly addressed.
- Proposal: We’ll provide you with a bespoke study design customized to your specific questions, targets, and therapeutics.
- Revision: We’ll work together to revise the study proposal, to meet your needs, budget, and timelines.
- Execute: Our highly interactive project managers will keep you up-to-date throughout the study.
Are You Ready to Discover Your Compound's Immunotherapeutic Potential
Citations
- Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365-5386. doi:10.7150/thno.58390.
Interested in learning more about theraTRACE®?
Interested in learning more about theraTRACE®?If you are interested in learning more about phenotypic screening and drug repositioning, please contact us to start the conversation today!
